×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRL – charles river laboratories international, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
05:06 pm
crl
Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know [Yahoo! Finance]
Low
Report
Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know [Yahoo! Finance]
12/1
09:02 pm
crl
Charles River Laboratories International (NYSE:CRL) was given a new $185.00 price target on by analysts at Morgan Stanley.
Low
Report
Charles River Laboratories International (NYSE:CRL) was given a new $185.00 price target on by analysts at Morgan Stanley.
12/1
03:42 pm
crl
HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Low
Report
HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
12/1
08:00 am
crl
Charles River Laboratories to Present at Evercore Healthcare Conference
Low
Report
Charles River Laboratories to Present at Evercore Healthcare Conference
11/24
12:53 pm
crl
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
Low
Report
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
11/21
08:37 am
crl
Madison Small Cap Fund Q3 2025 Portfolio Activity [Seeking Alpha]
Low
Report
Madison Small Cap Fund Q3 2025 Portfolio Activity [Seeking Alpha]
11/17
12:08 pm
crl
Charles River Laboratories International (NYSE:CRL) was given a new $200.00 price target on by analysts at Argus.
Low
Report
Charles River Laboratories International (NYSE:CRL) was given a new $200.00 price target on by analysts at Argus.
11/17
10:23 am
crl
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating.
Medium
Report
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
07:00 am
CRL
charles river laboratories international, inc.
BEAT
Report
-5.8%
charles river laboratories international, inc.
8/6/2025
07:00 am
CRL
charles river laboratories international, inc.
BEAT
Report
-11.6%
charles river laboratories international, inc.
5/7/2025
07:01 am
CRL
charles river laboratories international, inc.
BEAT
Report
13.2%
charles river laboratories international, inc.
2/19/2025
07:00 am
CRL
charles river laboratories international, inc.
BEAT
Report
6.0%
charles river laboratories international, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
07:29 am
crl
Form 8-K CHARLES RIVER LABORATORI For: Dec 03
Medium
Report
Form 8-K CHARLES RIVER LABORATORI For: Dec 03
11/17
08:06 am
crl
Form 8-K CHARLES RIVER LABORATORI For: Nov 14
Medium
Report
Form 8-K CHARLES RIVER LABORATORI For: Nov 14
11/14
04:59 pm
crl
Form SCHEDULE 13G/A CHARLES RIVER LABORATORI Filed by: NOMURA HOLDINGS INC
Medium
Report
Form SCHEDULE 13G/A CHARLES RIVER LABORATORI Filed by: NOMURA HOLDINGS INC
11/12
09:35 am
crl
Form SCHEDULE 13G/A CHARLES RIVER LABORATORI Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SCHEDULE 13G/A CHARLES RIVER LABORATORI Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/7
04:35 pm
crl
Form 4 CHARLES RIVER LABORATORI For: Nov 06 Filed by: Knell Michael Gunnar
Low
Report
Form 4 CHARLES RIVER LABORATORI For: Nov 06 Filed by: Knell Michael Gunnar
11/5
09:12 am
crl
Form 10-Q CHARLES RIVER LABORATORI For: Sep 27
Low
Report
Form 10-Q CHARLES RIVER LABORATORI For: Sep 27
11/5
07:16 am
crl
Form 8-K CHARLES RIVER LABORATORI For: Nov 05
Medium
Report
Form 8-K CHARLES RIVER LABORATORI For: Nov 05
9/19
04:15 pm
crl
Form 8-K/A CHARLES RIVER LABORATORI For: Sep 12
Low
Report
Form 8-K/A CHARLES RIVER LABORATORI For: Sep 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/11
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
11.8%
4/3 Immunologist says he has a possible cure for the coronavirus [FOX News] 8.9%
3/2 Charles River Laboratories Intl. Inc (NYSE: CRL) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $190.00 price target on the stock. 4.3%
3/30 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at Wells Fargo & Co from $200.00 to $145.00. They now have an "overweight" rating on the stock. 4.2%
3/4 Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors 4.0%
3/26 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at Barclays PLC from $170.00 to $154.00. They now have an "equal weight" rating on the stock. 3.9%
6/19 Laetose(TM), Healthier Sugar Naturally Modified From Table Sugar, Unveiled at Harvard Health Summit 3.5%
3/10 Charles River Laboratories To Participate In Barclays Global Healthcare Conference 3.2%
2/13 Charles River Laboratories Intl. Inc (NYSE: CRL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
11/8 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at UBS Group AG from $147.00 to $145.00. They now have a "neutral" rating on the stock. 2.5%
4/3 Immunologist says he has a possible cure for the coronavirus [FOX News] 8.9%
3/2 Charles River Laboratories Intl. Inc (NYSE: CRL) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $190.00 price target on the stock. 4.3%
3/30 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at Wells Fargo & Co from $200.00 to $145.00. They now have an "overweight" rating on the stock. 4.2%
3/4 Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors 4.0%
3/26 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at Barclays PLC from $170.00 to $154.00. They now have an "equal weight" rating on the stock. 3.9%
6/19 Laetose(TM), Healthier Sugar Naturally Modified From Table Sugar, Unveiled at Harvard Health Summit 3.5%
3/10 Charles River Laboratories To Participate In Barclays Global Healthcare Conference 3.2%
2/13 Charles River Laboratories Intl. Inc (NYSE: CRL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
11/8 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at UBS Group AG from $147.00 to $145.00. They now have a "neutral" rating on the stock. 2.5%
TOP News Decliners
3/19
Doctor says he's 3-4 weeks from developing treatment to 'neutralize' coronavirus [FOX News]
-18.6%
4/21 Charles River Laboratories Intl. Inc (NYSE: CRL) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. They now have a $139.00 price target on the stock. -6.4%
5/7 Q1/2019 3/30/2019 EPS 1.400 ZacksConsensus 1.380 ActVsEst 0.020 - Beat -5.7%
3/4 Form 3 CHARLES RIVER LABORATORI For: Mar 02 Filed by: Andrews Nancy C -4.9%
7/31 Q2/2019 6/29/2019 EPS 1.630 ZacksConsensus 1.550 ActVsEst 0.080 - Beat -4.5%
10/21 Charles River Laboratories Announces Offering of $500 Million of Senior Notes -4.4%
3/17 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at SunTrust Banks, Inc. from $188.00 to $124.00. They now have a "buy" rating on the stock. -4.0%
9/9 Charles River Laboratories Announces Updates to Microbial Solutions Product Portfolio -3.7%
10/1 Charles River Laboratories Adds Virginia M. Wilson to Board of Directors -3.2%
3/27 Charles River Laboratories Intl. Inc (NYSE: CRL) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $152.00 price target on the stock. -2.9%
4/21 Charles River Laboratories Intl. Inc (NYSE: CRL) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. They now have a $139.00 price target on the stock. -6.4%
5/7 Q1/2019 3/30/2019 EPS 1.400 ZacksConsensus 1.380 ActVsEst 0.020 - Beat -5.7%
3/4 Form 3 CHARLES RIVER LABORATORI For: Mar 02 Filed by: Andrews Nancy C -4.9%
7/31 Q2/2019 6/29/2019 EPS 1.630 ZacksConsensus 1.550 ActVsEst 0.080 - Beat -4.5%
10/21 Charles River Laboratories Announces Offering of $500 Million of Senior Notes -4.4%
3/17 Charles River Laboratories Intl. Inc (NYSE: CRL) had its price target lowered by analysts at SunTrust Banks, Inc. from $188.00 to $124.00. They now have a "buy" rating on the stock. -4.0%
9/9 Charles River Laboratories Announces Updates to Microbial Solutions Product Portfolio -3.7%
10/1 Charles River Laboratories Adds Virginia M. Wilson to Board of Directors -3.2%
3/27 Charles River Laboratories Intl. Inc (NYSE: CRL) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $152.00 price target on the stock. -2.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: